Big Pharma R&D is exiting China, but leaving a legacy; China's biotech execs couldn’t be happier
→ Bloomberg posted a story about the Big Pharmas that have been bailing out of China recently. We’ve been covering this step by step at Endpoints News, but it’s worth pointing out that the big outfits that entered China with such fanfare around 7 or 8 years ago accomplished very little of note with their R&D groups. They did, however, effectively train a whole generation of execs who are playing a big role in making the Asian giant a big new player in biopharma. That may not have been the payback they were looking for, but it is significant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.